Trending menu:
Comment
-
11 November 2019
Majority of Alzheimer’s disease clinical trials in the US parked in Phase I
Alzheimer’s disease is the most common type of dementia and the sixth leading cause of death in the US.
-
11 November 2019
Poseidon reaps success for AstraZeneca’s Imfinzi in non-small cell lung cancer
The trial will continue to assess the additional primary endpoint of overall survival, with data anticipated in 2020.
-
8 November 2019
AstraZeneca’s Flaura lung cancer results favour further first-line Tagrisso use
An EGFR mutation refers to a mutation (damage) to the portion of the DNA in a lung cancer cell which carries the "recipe" for making EGFR (epidermal growth factor receptor)...
-
8 November 2019
Ayala plans Phase II cancer studies to start by first half of 2020
The Phase II AL-101 TNBC study will begin in the first half of 2020.
-
1 November 2019
2018 was a top year for clinical trials for depression
Looking at depression clinical trials in the database with a start date from 2015 to present, 2018 had the most clinical trials.
-
1 November 2019
Benchmarking Phase II industry-sponsored pancreatic cancer trials
About 56,770 people in the US will be diagnosed with pancreatic cancer in 2019, according to the American Cancer Society.
-
30 October 2019
Top industry sponsors of checkpoint modulator trials
Checkpoint modulators, also known as checkpoint inhibitors, are drugs that play a pivotal role in cancer immunotherapy.
-
30 October 2019
Celldex stops Phase Ib/II trial in melanoma due to GI toxicities after enrolling three patients
The study had enrolled three out of its 10-patient target when it was stopped, a source said.
-
25 October 2019
Amgen’s AMG510 combo exploration in colorectal cancer tumours poised for late 2019, early 2020
The theory behind combining AMG510 with a MEK inhibitor in CRC is that together they would target upstream and downstream KRAS events.
-
24 October 2019
UCB to conduct bridging study of UCB0107 in progressive supranuclear palsy this year
The bridging study will be necessary to provide the safety and pharmacokinetic data needed to advance the anti-tau drug into a Phase III trial planned for 2020.